FDMM

9.8400.00%
MW

Michael William Porter

Independent Director

Mr. Michael William Porter, MBA is Director of Pressio, Inc. He is the Chief Executive Officer & Director at Covis Pharma B.V. He is Independent Director at Freedom Metals Acquisition Corp. since July 08, 2026. He serves as Director at Restor3D Inc. since 2024. Mr. Porter was involved in the original founding of Covis as the Senior Operating Executive and a member of the Board responsible for original sourcing, investment thesis and the forming of Covis in 2011 with initial complex carve-out from GlaxoSmithKline. Mr. Porter was previously COO of Covis in 2013 then became CEO in 2015. He serves as Chief Executive Officer at Covis Pharma, S.à.r.l. Mr. Porter serves as Chief Executive Officer, President and Director at AMAG Pharmaceuticals, Inc. since November 16, 2020. Mr. Porter has private equity experience. Prior to Covis, he was with Cerberus Capital Management where he was a Senior Operating Executive. Earlier in his career, Mr. Porter held senior roles at Cerberus, Sun Capital Partners LLP, AlixPartners, LLP and Schultze Asset Management, LLC. Mr. Porter has served as founder and board member of Pasos de Esperanza since 2008 on the Advisory Board of the Duke University MedTech Incubator since 2020, on the boards of Pressio Spine and Huxley Medical, two commercial-stage medical technology companies, since 2021 and on the board of directors of Restor3d, Inc., a pre-IPO innovative medical technology company, since 2023. Mr. Porter previously served as Chairman of the Board of Managers of Ciraparantag Holdings GmbH from 2022 to 2025. He was previously with another large distressed private equity fund and began his career at AlixPartners in their Turnaround and Performance Improvement Group. He served as a Director of Covis Pharma Holdings S.à.r.l. He received his MBA from Columbia Business School with a concentration in Finance via the accelerated program. In addition, he studied International Business at Senshu University in Kawasaki, Japan. Earlier in his career, Mr. Porter held senior roles at Cerberus, Sun Capital Partners LLP, AlixPartners, LLP and Schultze Asset Management, LLC. Mr. Porter has served as founder and board member of Pasos de Esperanza since 2008 on the Advisory Board of the Duke University MedTech Incubator since 2020, on the boards of Pressio Spine and Huxley Medical, two commercial-stage medical technology companies, since 2021 and on the board of directors of Restor3d, Inc., a pre-IPO innovative medical technology company, since 2023. Mr. Porter previously served as Chairman of the Board of Managers of Ciraparantag Holdings GmbH from 2022 to 2025.

Positions